Author:
Khan Mohammad Beigi Pooya
Publisher
Springer International Publishing
Reference31 articles.
1. Olsen E, Whittaker S, Kim Y, Duvic M, Prince H, Lessin S, et al. International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–607.
2. Freiman A, Sasseville D. Treatment of mycosis fungoides: overview. J Cutan Med Surg. 2006;10(5):228–33.
3. Galper SL, Smith BD, Wilson LD. Diagnosis and management of mycosis fungoides. Oncology. 2010;24(6):491.
4. Liu DY, Shaath T, Rajpara AN, Hanson C, Fraga G, Fischer R, et al. Safe and efficacious use of intralesional steroids for the treatment of focally resistant mycosis fungoides. J Drugs Dermatol. 2015;14(5):466–71.
5. Van Scott EJ, Kalmanson JD. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer. 1973;32(1):18–30.